LucyL
Member
- Joined
- Oct 21, 2013
- Messages
- 1,245
I think the zpak is doing the heavy lifting while HCQ is just chillin or having some mild anti viral effects. Secondary bacterial infection seems to be the main culprit here.
You might be correct - in light of this review
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30378-7/fulltext
Interpretation
We found no evidence of a difference in COVID-19 mortality among people who received hydroxychloroquine for treatment of rheumatological disease before the COVID-19 outbreak in England.
Though it did include this tidbit:We found no evidence of a difference in COVID-19 mortality among people who received hydroxychloroquine for treatment of rheumatological disease before the COVID-19 outbreak in England.
In unadjusted analyses, regular users of hydroxychloroquine had a decreased risk of COVID-19 mortality (HR 0·78, 95% CI 0·60–1·00, figure 4). After adjusting for age and sex, there was no longer any evidence of association (HR 1·08, 0·84–1·40).